A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma

被引：0
|
作者：
Salles, Gilles [1 ]
Shah, Harsh [2 ]
Leonard, John P. [3 ]
Szanto, Attila [4 ]
Chen, Jade [4 ]
Bannerji, Rajat [4 ]
Morschhauser, Franck [5 ]
Nastoupil, Loretta J. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Utah, Salt Lake City, UT USA
[3] Weill Cornell Med, New York, NY USA
[4] Epizyme, Cambridge, MA USA
[5] Univ Lille, CHU Lille, ULR 7365, GRITA,Grp Rech Formes Injectables & Technol Assoc, Lille, France
[6] UT MD Anderson Canc Ctr, Houston, TX USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
IBCL; follicular lymphoma; non-Hodgkin lymphoma; enhancer of zeste homolog 2 protein; epigenetics; tazemetostat; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-485
引用
收藏
页码：S454 / S455
页数：2
相关论文
共 50 条
  • [31] RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.
    Fowler, Nathan Hale
    Morschhauser, Franck
    Feugier, Pierre
    Bouabdallah, Reda
    Tilly, Herve
    Palomba, Maria Lia
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study
    Zelenetz, Andrew D.
    Robak, Tadeusz
    Coiffier, Bertrand
    Delgado, Julio
    Marlton, Paula
    Adewoye, Adeboye H.
    Kim, Yeonhee
    Dreiling, Lyndah K.
    Hillmen, Peter
    BLOOD, 2015, 126 (23)
  • [33] A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab plus Galiximab Vs Rituximab plus Placebo In Advanced Follicular Non-Hodgkin's Lymphoma (NHL)
    Bence-Bruckler, Isabelle
    Macdonald, David
    Stiff, Patrick J.
    McKinney, Byron
    Ruffner, Katherine L.
    Wilson, Lynn
    Whiteley, Margaret
    Kahl, Brad
    BLOOD, 2010, 116 (21) : 191 - 192
  • [34] Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study
    Zelenetz, A.
    Robak, T.
    Coiffier, B.
    Delgado, J.
    Marlton, P.
    Adewoye, A.
    Kim, Y.
    Dreiling, L.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 10 - 10
  • [35] Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
    Morschhauser, Franck
    Tilly, Herve
    Chaidos, Aristeidis
    Phillips, Tycel J.
    Ribrag, Vincent
    Campbell, Philip
    Laurent, Damaj Gandhi
    Jurczak, Wojciech
    McKay, Pamela
    Opat, Stephen
    Radford, John
    Whalen, Jennifer
    Rajarethinam, Anand
    Navia, Susan Benedict
    Adib, Deyaa
    Salles, Gilles
    BLOOD, 2019, 134
  • [36] Subgroup analyses of patients aged ≥70 years in AUGMENT: Phase III randomized study of Lenalidomide plus rituximab (R2) vs rituximab plus placebo (R-placebo) in patients with Relapsed/Refractory (R/R) indolent Non-Hodgkin Lymphoma (iNHL)
    La Rosee, P.
    Graeven, U.
    Leonard, J. P.
    Gribben, J.
    Zhang, H.
    Nowakowski, G.
    Izutsu, K.
    Fowler, N. H.
    Thieblemont, C.
    Zinzani, P. L.
    Kalambakas, S.
    Fustier, P.
    Wu, C.
    Trneny, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 68 - 68
  • [37] Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma
    Hari, Parameswaran
    Lin, Huamao Mark
    Zhu, Yanyan
    Berg, Deborah
    Richardson, Paul G.
    Moreau, Philippe
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 793 - 798
  • [38] Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
    Matasar, Matthew J.
    Capra, Marcelo
    Ozcan, Muhit
    Lv, Fangfang
    Li, Wei
    Yanez, Eduardo
    Sapunarova, Katya
    Lin, Tongyu
    Jin, Jie
    Jurczak, Wojciech
    Hamed, Aryan
    Wang, Ming-Chung
    Baker, Ross
    Bondarenko, Igor
    Zhang, Qingyuan
    Feng, Jifeng
    Geissler, Klaus
    Lazaroiu, Mihaela
    Saydam, Guray
    Szomor, Arpad
    Bouabdallah, Krimo
    Galiulin, Rinat
    Uchida, Toshiki
    Soler, Lidia Mongay
    Cao, Anjun
    Hiemeyer, Florian
    Mehra, Aruna
    Childs, Barrett H.
    Shi, Yuankai
    Zinzani, Pier Luigi
    LANCET ONCOLOGY, 2021, 22 (05): : 678 - 689
  • [39] CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.
    Nastoupil, Loretta J.
    Morschhauser, Franck
    Scholz, Christian W.
    Bishton, Mark
    Yoon, Sung-Soo
    Giri, Pratyush
    Wei, Michael C.
    Knapp, Andrea
    Li, Chi-Chung
    Bottos, Alessia
    Li, Haocheng
    Purev, Enkhtsetseg
    Bartlett, Nancy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] A match-adjusted indirect treatment comparison of lenalidomide plus rituximab versus rituximab plus chemotherapy for relapsed and/or refractory follicular lymphoma.
    Fox, Christopher P.
    Arcaini, Luca
    Hernandez-Ilizaliturri, Grancisco
    Tabah, Ashley
    Parker, Christopher
    Jones, Jeffrey
    Abouzaid, Safiya
    Watkins, Claire
    Bachy, Emmanuel
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S29 - S30
12345